Media stories about Matinas BioPharma Holdings (NASDAQ:MTNB) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Matinas BioPharma Holdings earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.4535592244681 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several analysts have issued reports on the stock. Roth Capital assumed coverage on shares of Matinas BioPharma Holdings in a research report on Monday, July 10th. They set a “buy” rating and a $9.00 price target for the company. Maxim Group restated a “buy” rating and set a $6.00 price target on shares of Matinas BioPharma Holdings in a research report on Monday, June 26th.
Matinas BioPharma Holdings (NASDAQ:MTNB) traded down 3.05% during mid-day trading on Friday, hitting $1.27. 80,822 shares of the stock were exchanged. Matinas BioPharma Holdings has a 52 week low of $1.01 and a 52 week high of $3.99. The company’s 50-day moving average price is $1.31 and its 200 day moving average price is $2.00. The firm’s market capitalization is $113.10 million.
Matinas BioPharma Holdings (NASDAQ:MTNB) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. Matinas BioPharma Holdings had a negative net margin of 8,834.65% and a negative return on equity of 143.22%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.02 million. Equities research analysts expect that Matinas BioPharma Holdings will post ($0.29) EPS for the current year.
In other Matinas BioPharma Holdings news, Director Adam K. Stern purchased 100,000 shares of the stock in a transaction dated Friday, September 8th. The stock was purchased at an average price of $1.38 per share, with a total value of $138,000.00. Following the transaction, the director now owns 793,992 shares of the company’s stock, valued at $1,095,708.96. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 110,000 shares of company stock valued at $151,250 in the last ninety days.
About Matinas BioPharma Holdings
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.